EMA: No AUC(0-72h) for all MR products [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2023-10-18 09:09 (131 d 10:34 ago) – Posting: # 23764
Views: 1,040

Hi JP2030,

❝ Please share your opinion on Delayed-Release Tablets can we use study design AUC truncated at 72 h (AUC(0-72h)) for EU Submission? It's acceptable.

❝ Terminal Elimination Half-Life (T1/2el) of the drug is 67 hrs.

See the applicable guideline page 25:

A truncated AUC(0-72h) is not acceptable for MR products.

On page 26:

Single dose: AUC(0-t), AUC(0-∞), Cmax

Scientifically this does not make sense for DR products…

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,912 posts in 4,806 threads, 1,635 registered users;
23 visitors (1 registered, 22 guests [including 3 identified bots]).
Forum time: 18:43 CET (Europe/Vienna)

[…] an inappropriate study design is incapable of answering
a research question, no matter how careful the subsequent
methodology, conduct, analysis, and interpretation:
Flawless execution of a flawed design achieves nothing worthwhile.    J. Rick Turner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5